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In the current study, we investigated the nature and
role of CD44 variant isoforms involved in endothelial
cell (EC) injury and tumor cell cytotoxicity mediated by
IL-2-activated killer (LAK) cells. Treatment of CD44
wild-type lymphocytes with IL-2 led to increased gene
expression of CD44 v6 and v7 variant isoforms and to
significant induction of vascular leak syndrome (VLS).
CD44v6-v7 knockout (KO) and CD44v7 KO mice showed
markedly reduced levels of IL-2-induced VLS. The de-
creased VLS in CD44v6-v7 KO and CD44v7 KO mice did
not result from differential activation and expansion of
CD8 T cells, NK, and NK-T cells or from altered degree
of perivascular lymphocytic infiltration in the lungs.
LAK cells from CD44v7 KO mice showed a significant
decrease in their ability to adhere to and mediate lysis
of EC but not lysis of P815 tumor cells in vitro. CD44v7-
mediated lysis of EC by LAK cells was dependent on the
activity of phosphatidylinositol 3-kinase and tyrosine
kinases. Interestingly, IL-2-activated LAK cells express-
ing CD44hi but not CD44lo were responsible for EC lysis.
Furthermore, lysis of EC targets could be blocked by
addition of soluble or enzymatic cleavage of CD44v6-v7-
binding glycosaminoglycans. Finally, anti-CD44v7 mAbs
caused a significant reduction in the adherence to and
killing of EC and led to suppression of IL-2-induced VLS.
Together, this study suggests that the expression of
CD44v7 on LAK cells plays a specific role in EC injury
and that it may be possible to reduce EC injury but not
tumor cell killing by specifically targeting CD44v7.
Endothelial cell (EC)1 injury is a widely occurring patholog-
ical condition seen during a variety of infections, autoimmu-
nity, transplantation, and graft-versus-host disease and follow-
ing immunotherapy with cytokines and immunotoxins (1–6). It
is becoming increasingly clear that EC injury results from
cytotoxicity of EC mediated by immune effector lymphocytes
(7–10). Interleukin-2 (IL-2) therapy has been shown to be ef-
fective against human melanomas and renal cell carcinomas
(11–13). It is also being tested to treat AIDS and other viral
infections (14). However, IL-2 therapy is also accompanied by
severe life-threatening toxicity characterized by EC injury
leading to capillary or vascular leak syndrome (VLS) (11, 15,
16).
CD44 is a widely distributed cell surface glycoprotein ex-
pressed by a variety of lymphoid and non-lymphoid cells. CD44
is involved in a number of processes including lymphocyte
migration and extravasation, lymph node homing, and lympho-
cyte activation (17, 18). CD44 is coupled to at least two tyrosine
kinases, suggesting that it can directly act as a signaling mol-
ecule (19). Studies from our laboratory demonstrated that liga-
tion of CD44 triggers lytic activity in activated CD8 cytotoxic
T lymphocytes as well as in double-negative T cells that accu-
mulate in lpr/lpr mice (20–22). Other studies showed that
treatment with anti-CD44 mAbs increases the lytic activity of
natural killer (NK) cells (23, 24). In addition, reports suggest
that CD44 plays an important role in adherence of lymphokine-
activated killer (LAK) cells to tumor targets (25). Initial studies
from our laboratory examining the role of CD44 in IL-2-induced
VLS revealed that the induction of VLS in CD44 KO mice was
significantly reduced when compared with CD44 wild-type
(WT) mice (10). Together, these observations suggested that
activation through CD44 can enhance the effector functions of
T lymphocytes and NK cells and that this may lead to the
increased EC injury leading to VLS as well as effective killing
of tumor cells. However, the precise nature of CD44 isoforms
involved in EC injury and the cytotoxicity of tumor cells is
not clear.
The standard form of CD44, designated CD44s, is the most
common form and has a size of 85–95 kDa (26). In addition to
CD44s, a number of larger CD44 isoforms, ranging in size from
80 to 250 kDa, develop as a result of alternative splicing of
variant exons (27). It has been suggested that expression of
specific isoforms may play a role in the regulation of the im-
mune response as well as in the development of autoimmune
disorders. For example, CD44v7 has been shown to be involved
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in the production of cytokines by B cells and to play a role in the
interaction of T cells with antigen-presenting cells, and progen-
itor cells with stromal cells (17, 28). Other isoforms of CD44,
such as CD44v6 and CD44v9, were shown to be involved in B
cell adhesion to stromal cells (29). Treatment with anti-CD44v7
antibodies can inhibit the production of IL-2 and interferon-
by CD8 cells (28). In addition, studies have shown that trini-
trobenzene sulfonate-induced colitis can be prevented and
cured by treatment with anti-CD44v7 mAbs (30). Therefore, it
is possible that specific CD44 variant isoforms play a role in
mediating EC damage seen in disorders such as VLS.
In the current study, we examined whether specific CD44
isoforms play a role in mediating IL-2-induced VLS and tumor
cytotoxicity. To this end, we screened splenocytes from mice
treated with high doses of IL-2 for the expression of various
CD44 isoforms and used CD44 variant knockout (KO) mice to
examine whether the absence of specific isoforms would lead to
reduced level of VLS. The results from this study demonstrated
that CD44v7 plays an important role in the induction of vas-
cular leak and EC damage following IL-2 treatment and that
antibodies directed against CD44v7 can block IL-2-induced EC
damage and VLS. Interestingly, CD44v7 did not play a role in
the cytotoxicity of P815 tumor cells mediated by LAK cells.
Together, the information in this study suggests that strategies
designed to target the expression of CD44v7 may help to pre-
vent EC damage seen in a variety of disorders.
MATERIALS AND METHODS
Mice—Adult female C57BL/6 (CD44 WT) mice were purchased from
the National Institutes of Health (Bethesda, MD). CD44 KO mice rep-
resent those in which the entire CD44 gene is deleted; therefore, such
mice fail to express all CD44 isoforms (10, 31). CD44v7 KO and
CD44v6-v7 mice are those with targeted deletion of CD44v7 or CD44v6
and -v7 exon products, respectively. Such mice, therefore, fail to express
CD44 isoforms bearing the variant exon v7 or v6 and v7, respectively
(30). All these strains were on C57BL/6 background. The CD44 KO,
CD44v6-v7 KO, and CD44v7 KO mice were bred in the animal facilities
at the Medical College of Virginia Campus, Virginia Commonwealth
University, and screened for the CD44, CD44v6-v7, and CD44v7 dele-
tion, respectively. TIE2-GFP mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). These mice express green fluorescent
protein (GFP) under the control of the endothelial-specific receptor
tyrosine kinase (TIE2) promoter (32).
Cell Lines—TME (an endothelial cell line; H-2K), SVC3H (a fibroblast
cell line; H-2K), and P815 (a mastocytoma) were maintained in vitro by
serial passage in RPMI 1640 containing 10% FCS as described (33).
RNA Isolation and RT-PCR Analysis—Total RNA was isolated from
single cell suspension of splenocytes using the RNeasy Mini Kit (Qia-
gen, Valencia, CA). RNA concentration was determined spectrophoto-
metrically, and the integrity of the each preparation was verified by
agarose gel electrophoresis. cDNA was synthesized by reverse tran-
scription of 50 ng of total RNA using the SensiScript RT Kit (Qiagen).
All PCR reactions were prepared using MasterAmp PCR Premix F
(Epicenter Technologies, Madison, WI) according to the recommenda-
tions from the manufacturer, and using Platinum TaqDNA polymerase
(Invitrogen, Carlsbad, CA). A half-nested RT-PCR approach was used to
amplify CD44 isoforms, as endogenous isoform expression is too low to
be detected directly by RT-PCR (data not shown). An initial amplifica-
tion using primers CD44 U and CD44 L, homologous to the 5 and 3
standard regions of the CD44 gene, was used to amplify both CD44
standard form and all isoforms. The products of this reaction were used
as template in a second reaction using a CD44 isoform-specific primer
in conjunction with the appropriate CD44 standard region primer
(CD44 L and CD44 isoform U). The primers used are described in
Table I.
Cloning and DNA Sequencing—PCR products were cloned using the
TOPO TA Cloning Kit (Invitrogen). After overnight incubation at 37 °C
on LB plates containing ampicillin (100 g/ml) and 5-bromo-4-chloro-
3-indolyl--D-galactopyranoside (X-gal), positive (white) colonies were
subcultured in 300 l of LBamp100 medium at 37 °C for 4 h. Two l of
each culture was used as template in a PCR reaction to confirm the
presence of an insert. Cultures containing CD44 isoform products were
grown overnight in 3 ml of LBamp100 medium. Plasmids were isolated
using the Spin Miniprep Kit (Qiagen). Plasmids were sequenced using
the M13 Reverse and M13 Forward (40) primers, and using ABI
BigDye terminator (version 2) chemistry (Applied Biosystems, Foster
City, CA).
Antibodies—PE- or FITC-conjugated anti-CD3, anti-CD4, anti-CD8,
anti-CD16 (Fc block), anti-CD19, anti-CD25, anti-CD44, Mac-3, and
anti-NK1.1 mAbs were purchased from Pharmingen (San Diego, CA).
Anti-CD44v7 mAbs (LN7.1) were prepared as previously described (34).
Briefly, CD44v6-v7 KO mice were immunized with 100–200 g of
CD44v4-v10/glutathione S-transferase (GST) fusion protein, three
times over a 12-day period. Two days following the last immunization,
the cells from the regional lymph nodes were fused using the X63-Ag8
cell line. The epitope recognized by LN7.1 was mapped and was shown
to recognize the following peptide located within the CD44v7 region:
QEDVSWTDFFDPISHP (30). The mAbs were purified from cell culture
supernatants using protein G-Sepharose columns (Amersham Bio-
sciences), and isotypes of the mAbs were determined using commer-
cially available kits (Serotec, Roche Molecular Biochemicals) (30). Iso-
type control mAbs (mouse IgG1) were purchased from Pharmingen.
Interleukin-2—Recombinant IL-2 was provided by the NCI Biological
Resources Branch (Rockville, MD).
Flow Cytometric Analysis of Cell Surface Markers and Cell Sorting—
Splenocytes from mice treated with high dose IL-2, as described below,
or splenocytes stimulated with IL-2 in vitro were analyzed for the
expression of various cell surface markers. Nonspecific staining was
TABLE I
Sequences, amplicon sizes, and annealing temperatures of RT-PCR primers
Gene Primer name Sequence (5–3) Length Tm
bp °C
-Actin BA U AAGGCCAACCGTGAAAAGATGACC 427 60
BA L ACCGCTCGTTGCCAATAGTGATGA
Perforin Perf U GCTCCGGCTCCTTCCCAGTG 514 60
Perf L GCCGTGATAAAGTGCGTGCCATAG
TNF- TNF A U CAGGGGCCACCACGATCTTC 516 60
TNF A L TTGCCCCGCTTACAGTTCCTCTTT
FasL FasL U GGGCTCCTCCAGGGGTCAGTT 435 58
FasL L GAGCGGTTCCATATGTGTCTTCC
CD44 CD44 U GCACCCCAGAAGGCTACATTTT 328a 57
CD44 L TTCTGCCCACACCTTCTCCTACTA
CD44v3 v3 U TACGGAGTCAAATACCAACC Variableb 46
v3 L ATAAAATCTTCATCATCATCAAT Variable 45
CD44v6 v6 L CCCTTCGTCACATGGGAGTCTTC Variable 57
CD44v5 v5 U GGACCCCGGAACCACAGC Variable 56
CD44v7 v7 U TTCGGCCCACAACAACCA Variable 55
v7 L GATGTGAGATTGGGTCGAAGAAAT Variable 55
CD44v8 v8 U GCCTACTGCAGCTCCAAATA Variable 55
a CD44S (standard form). These primers also amplify CD44 isoforms containing alternatively spliced exons, but the standard form is of lower
molecular weight and more abundant, and is therefore preferentially amplified by PCR.
b Multiple PCR products of variable size were generated when using variable exon-specific primers in conjunction with conserved region primers
because of the inclusion of other alternatively spliced exons. See Fig. 1 for a depiction of the PCR strategy.
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blocked by incubation of the cells with Fc block (Pharmingen) for 15
min. The expression of various cell surface markers were determined by
staining the cells with FITC- or PE-conjugated mAbs for 30 min on ice,
followed by washing three times. The cells (5000) were analyzed by flow
cytometry. In experiments in which CD44 cell expressing low (CD44lo)
and high (CD44hi) levels of CD44 were separated, nonspecific staining
was blocked by incubation of the cells with Fc block (Pharmingen) for 15
min. Next, the cells were stained with PE-conjugated anti-CD44 mAbs
(IM7) for 30 min on ice and washed twice with PBS. The CD44lo and
CD44hi cells were separated using an Epics 753 cell sorter (Beckman
Coulter, Fullerton, CA).
Quantification of Vascular Leak Syndrome—Vascular leak was stud-
ied by measuring the extravasation of Evan’s blue, which, when given
intravenously, binds to plasma proteins, particularly albumin, and
following extravasation can be detected in various organs as described
previously (10, 35, 36). Vascular leak was induced by injection of IL-2 as
previously described (9, 10). Groups of five mice were injected intrap-
eritoneally with 75,000 units of rIL-2 or PBS as a control, three times a
day for 3 days. On day 4, the mice received one injection and 2 h later
were injected intravenously with 0.1 ml of 1% Evan’s blue in PBS. After
2 h, the mice were exsanguinated under anesthesia, and the heart was
perfused with heparin in PBS as described previously (37). The lungs
were harvested and placed in formamide at 37 °C overnight. The Evan’s
blue in the organs was quantified by measuring the absorbance of the
supernatant at 650 nm with a spectrophotometer. In experiments ex-
amining the effect of anti-CD44v7 mAbs on IL-2-induced VLS, mice
were treated with isotype control mAbs or anti-CD44v7 mAbs (100
g/mouse daily). In adoptive transfer experiments, CD44 WT and
CD44v7 KO mice were injected intravenously with splenocytes (5 
107) isolated from CD44 WT or CD44v7 KO mice (10). Next, the recip-
ient mice received IL-2 treatment (75,000 units, three times a day for 3
days) or PBS as described above, and on day 4, the mice were studied for
VLS induction. The VLS seen in IL-2-treated mice was expressed as
percentage of increase in extravasation when compared with that of
PBS-treated controls and was calculated as: [(optical density of dye in
the lungs of IL-2-treated mice)  (optical density of dye in the lungs of
PBS-treated controls)]/(optical density of dye in the lungs of PBS-
treated control)  100. Each mouse was individually analyzed for
vascular leak, and data from five mice were expressed as mean  S.E.
percentage increase in VLS in IL-2 treated mice when compared with
that seen in PBS-treated controls (9, 10).
Histological Analysis—Groups of three mice were injected with IL-2
or PBS as described earlier, and on day 4, the lungs were fixed in 10%
formalin solution. The organs were embedded in paraffin, sectioned,
and stained with hematoxylin and eosin, as described (9, 10). Perivas-
cular infiltration was scaled by counting the number of lymphocytes
infiltrating the vessel and averaging the minimum and maximum
range for each group. Four samples per mouse were analyzed, and a
minimum of four mice were included.
Mitogen Stimulation and Cell Proliferation—Spleen cells (5  105)
from CD44 WT, CD44v6-v7 KO, or CD44v7 KO mice were cultured for
48 h in the presence of ConA (5 g/ml), IL-2 (100 units/ml), or hyalu-
ronic acid (HA; 0–0.5 mg/ml) in 0.2 ml of medium containing 10% FCS.
The cells were pulsed with 2 Ci of [3H]thymidine during the final 8 h
of culture. The cells were then harvested using a cell harvester, and the
labeled DNA was determined using a liquid scintillation counter.
Generation of LAK Cells—Spleens were harvested from CD44 WT
and CD44v7 KO mice and were prepared into a single cell suspension
using a laboratory homogenizer (Stomacher, Tekmar, Cincinnati, OH).
Contaminating erythrocytes were removed by resuspending the cells in
3 ml of red blood cell lysing buffer (Sigma) for 5 min and then washing
three times in RPMI containing 10% FBS. After the third wash, the
viable spleen cells were quantified by trypan blue dye exclusion and
counting using a hemocytometer. The splenocytes were adjusted to 5 
106/ml and were cultured in vitro for 48 h with 1000 units/ml IL-2 in
RPMI containing 10% FBS. The cells were harvested, and viable cells
were purified by density gradient centrifugation using Ficoll-Hypaque
(Sigma). Such cells will be referred to as LAK cells. For generation of
LAK cells in vivo, CD44 WT and CD44v7 KO mice were treated with
IL-2 as described above. On day 4, the spleens from IL-2-treated mice
were harvested and prepared into a single-cell suspension, as described
above. LAK cells generated in vitro and in vivo were tested for cytotox-
icity against P815 tumor, SVC3H fibroblast, or TME EC targets using
the 51Cr release assay. Briefly, 1  106 target cells were labeled with
51NaCrO4 at 37 °C for 1 h. The LAK cells were plated in triplicate into
96-well round-bottomed plates at varying effector to target ratios and
incubated for 4 h at 37 °C. In these experiments the LAK cells are
defined as the effector cells that mediate lysis of the 51NaCrO4-labeled
EC or tumor cells, which are defined as the target cells. In experiments
examining the effect of anti-CD44v7 mAbs on the LAK activity, soluble
anti-CD44v7 mAbs or isotype control mAbs were added to the LAK cells
1 h prior to the addition of the EC targets. In experiments examining
the effects of soluble glycosaminoglycans on LAK activity, the various
glycosaminoglycans including chondroitin sulfate A, B, and C, heparin,
hyaluronate, and hyaluronate (Sigma) were added to the cultures at the
initiation of the 4-h assay. In experiments examining the effects of
wortmannin (Sigma) and herbimycin (Sigma) on LAK activity, the
inhibitors were added at the initiation of the 4-h assay. Spontaneous
release was determined by culturing the target cells alone, and the total
release was determined by incubating the target cells with 1% Triton
X-100. The supernatants were harvested after 4 h, and the radioactivity
was measured using a  counter.
HA Binding Studies—HA was bound to Covalink NH plates using
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (Pierce) (29). Briefly,
100 l of HA (100 g/ml) mixed with 50 l of 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide and 50 l of HCl (0.4 mM) were added to
individual wells of a 96-well plate and incubated for 2 h at room
temperature. The plates were washed and stored at 4 °C before use in
adhesion assays. To determine the level of adherence following stimu-
lation with IL-2, splenocytes from untreated and IL-2-treated lympho-
cytes were labeled for 4 h with [3H]thymidine (5 Ci/ml). The labeled
splenocytes (105/well) were added to each well and incubated for 1 h at
37 °C. Non-adherent cells were removed by gently pipetting with PBS.
The percentage of cells adhering to the plate was determined using the
following formula: [(counts/min (cpm) of cells adhering to HA-coated
plates  cpm of cells adhering to non-coated plates)/total cpm (non-
adherent cells plated on non-coated plates)]  100%.
Enzymatic Treatment—To examine the effect of enzymatic cleavage
of glycosaminoglycans on LAK activity, chondroitinase AC (0.02 units/
ml), chondroitinase B (0.02 units/ml), chondroitinase C (0.02 units/ml),
heparinase (0.02 units/ml), or hyaluronidase (100 rTRU/ml) was added
at the initiation of the 4-h 51Cr release assay. The enzymes were
purchased from Sigma. In assays in which EC and LAK cells were
pretreated with hyaluronidase (100 rTRU/ml), the cells were treated for
1 h at 37 °C, after which time the cells were washed with RPMI 1640
medium containing 10% FCS and tested in the 51Cr release assay.
Cell Adhesion Assay—EC were plated at 1 104/well and cultured at
37 °C overnight in a 96-well flat-bottomed plate. LAK cells generated in
vitro as described earlier were independently cultured for 16 h in the
presence of 5 Ci of [3H]thymidine. The LAK cells were washed and
added to the empty wells (total [3H]thymidine activity) or wells con-
taining EC cultures and incubated for 2 h at 37 °C. In experiments
examining the effect of anti-CD44v7 mAbs on the LAK cell adhesion to
EC, soluble anti-CD44v7 mAbs or isotype control mAbs were added to
the LAK cells 1 h prior to culture on EC-coated plates. LAK cells not
adhering to EC cells were removed by gently washing the cultures with
medium. Washing was performed by removing the initial medium fol-
lowed by two washing steps, which consisted of gentle pipetting with
100 l of medium. Adherent cells were quantified by measuring the
[3H]thymidine activity and compared with the [3H]thymidine activity of
cells removed from wells without EC (total activity). The percentage of
LAK cells adhering to the EC was determined using the following
formula: (cpm of adhering cells/cpm of total activity)  100.
Cell Aggregation—Cell aggregation was visualized using a protocol
as described by Matsumoto et al. (25). In experiment using TME EC,
LAK cells were labeled with carboxyfluorescein diacetate succinimidyl
ester (CFSE; Molecular Probes, Eugene, OR) and EC were labeled with
PKH26-GL fluorescent cell linker compound (PKH, Sigma-Aldrich). In
experiments using GFP-positive EC isolated from TIE2-GFP mice, LAK
cells were labeled with PKH and mixed with EC that constitutively
express GFP. EC (1  106/ml) and LAK cells (4  106/ml) were mixed
together in equal volumes (total volume of 1 ml) and centrifuged for 10
min at 500 rpm. The resulting pellets were cultured for 10 min at 37 °C
to facilitate cell aggregation. To stop cell aggregation, the pellets were
resuspended in ice-cold PBS. Cell aggregation was visualized using a
fluorescent microscope (Nikon, Melville, NY) by overlaying images of
red fluorescence (PKH) with images of green fluorescence (CFSE or
GFP). In experiments using GFP and PKH, PKH-positive cells are
depicted as yellow following overlay of the images. Quantification of cell
aggregation was performed by determining the percentage of EC con-
jugated to at least one LAK cell in 10 random fields. The results were
depicted as percentage of cell aggregation and was calculated as: (num-
ber of endothelial cells per field conjugated to at least one LAK cell)/
(total number of endothelial cells per field)  100.
EC Isolation—EC were isolated from TIE2-GFP mice using methods
described by Marelli-Berg et al. (38). Briefly, lungs were isolated from
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TIE2-GFP mice, mechanically dissected, and digested in collagenase
(0.5 mg/ml) for 1 h at 37 °C. The cells were washed twice in PBS
containing 2.5% FCS and incubated with murine serum to block Fc
receptors. The cells were cultured with rat anti-mouse CD31 and
CD105 mAbs as well as biotinylated isolectin B4 for 30 min on ice. Next,
the cells were washed and cultured with goat anti-rat IgG-conjugated
microbeads and streptavidin-conjugated microbeads for 15 min on ice.
The cells were then passed through a MACS separation unit, and the
cells magnetically retained were eluted. The purity of EC was confirmed
by analyzing the cells for GFP using a flow cytometer, and the EC
preparation was found to be 95% GFP-positive.
Statistical Analysis—Analysis of variation and Student’s t test were
used to determine statistical significance, and p  0.05 was considered
to be statistically significant.
RESULTS
Up-regulation of CD44v7 and CD44v6-v7 Variant Isoforms
after IL-2 Treatment in Vivo—To determine whether IL-2
treatment led to the differential regulation of CD44 variant
isoform expression, spleen cells from CD44 WT mice injected
with IL-2 or PBS, as described under “Materials and Methods,”
were harvested on day 4 and analyzed for the expression of
various CD44 isoforms. The results showed that treatment
with IL-2 in vivo led to the expression of a number of CD44
variant isoforms (Fig. 1). Most notable was the dramatic induc-
tion of isoforms containing alternatively spliced exons v6 and
v7 (compare PBS versus IL-2; see Fig. 1, panels 1, 2, 4, and 5).
Amplification using a v7 reverse primer and CD44 conserved
region forward primer (Fig. 1, panel 1) did not yield a product
in PBS-treated sample. However, in IL-2-treated samples,
products of 191 and 317 bp were generated. Cloning and se-
quence analysis of these products revealed them to be isoforms
containing v7 alone and v6-v7, respectively. Similarly, ampli-
fication using a v7 forward primer and CD44 conserved region
reverse primer also yielded no product in the PBS-treated
sample. Cloning and sequence analysis revealed that the faint
band seen in the PBS lane (Fig. 1, panel 2) is a nonspecific
artifact, resulting from the half-nested amplification strategy
used. Two products of 288 and 459 bp were generated in the
IL-2-treated samples, which, following cloning and sequencing,
were revealed to contain v7 alone and v7-v8, respectively.
CD44v6 isoforms were amplified using a v6 reverse primer and
CD44 conserved region forward primer (Fig. 1, panel 5). A
328-bp product was amplified in the PBS-treated sample,
which was found to contain exons v6 and v5. Amplification of
the IL-2-treated sample resulted in products of 211, 328, and
410 bp. Sequencing of the 211-and 328-bp products revealed
them to be v6 alone and v6-v5, respectively. The expression of
v6 and v5 was confirmed by amplification using a v5-specific
forward primer and CD44 conserved region reverse primer
(Fig. 1, panel 4). No products were amplified in the PBS-treated
sample; however, bands of 310 and 436 bp were amplified from
IL-2-treated samples. Sequencing of these products confirmed
them to be v5 alone and v5-v6. In addition, IL-2 treatment
resulted in up-regulation of isoforms containing v8 and v8-v9
(Fig. 1, panel 3). Isoforms containing v3 were found to be
constitutively expressed, and were not affected by IL-2 treat-
ment (Fig. 1, panels 6 and 7).
Decreased VLS in CD44v7 KO and CD44v6-v7 KO Mice—To
investigate the role of CD44v7 and CD44v6 isoforms in IL-2-
induced VLS, CD44 WT, CD44 KO, CD44v7 KO, and
CD44v6-v7 KO mice were injected with 75,000 units of IL-2
three times daily for 3 days and once on day 4. On the last day,
the mice were injected with 1% Evan’s blue and VLS was
studied by determining the extravasation of the dye in the
lungs. Fig. 2 shows a representative experiment in which the
CD44 WT mice displayed significant VLS following IL-2 treat-
ment and CD44 KO mice showed marked decrease in VLS as
reported previously (10). Interestingly, the CD44v7 KO and
CD44v6-v7 KO mice also exhibited significantly lower levels of
VLS in the lungs. The decreased VLS seen in CD44v7 KO mice
was similar to that observed in CD44 KO and CD44v6-v7 KO
mice, suggesting that the product of the v7 exon may play a
specific role in the induction of IL-2-induced VLS. Inasmuch as,
in an earlier study we had extensively investigated the IL-2-
induced VLS in CD44 KO mice (10), all subsequent experi-
ments were confined to CD44v7 KO and CD44v6-v7 KO mice.
Histological Analysis of Lungs from IL-2-treated Mice—Pre-
vious studies demonstrated that IL-2 treatment triggered
marked infiltration of lymphocytes and macrophages in the
lungs (9, 10). Histological studies were therefore conducted to
determine whether the reduced levels of VLS seen in CD44v7
KO and CD44v6-v7 KO mice were caused by an alteration in
the migration of mononuclear cells into the lungs. Mice were
injected with PBS or IL-2, as described in Fig. 2. On day 4, the
FIG. 1. RT-PCR-based characterization of CD44 isoform expression in IL-2-activated splenocytes. RNA isolated from splenocytes of
PBS-treated and IL-2-treated mice was subjected to RT-PCR analysis using the PCR strategy depicted above and the primer sets listed in Table
I. PCR products were resolved on 1.2% agarose gels. The alternatively spliced exons comprising the PCR products from each reaction, confirmed
by sequence analysis, are listed to the right of the gel images along with the length of each product in base pairs. The results of each PCR reaction,
containing a pool of alternatively spliced isoforms, was cloned into the TOPO-TA vector, and positive colonies screened by PCR. Colonies containing
CD44 isoforms were then sequenced in both directions using SP6 and T7 primers.
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lungs were harvested and stained with hematoxylin and eosin
(Fig. 3, A–D). The lungs from the PBS-treated mice did not
show any perivascular infiltration. In contrast, the IL-2-
treated CD44 WT mice exhibited significant perivascular infil-
tration consisting mainly of lymphocytes around the pulmo-
nary vein. In comparison, the lungs from CD44v7 KO and
CD44v6-v7 KO mice treated with IL-2 showed similar levels of
perivascular infiltration as the IL-2-treated CD44 WT mice
(Fig. 3E). These data suggested that the decrease in IL-2-
induced VLS seen in CD44v7 KO and CD44v6-v7 KO mice was
not the result of alterations in the ability of mononuclear cells
to infiltrate into the lungs.
The Effect of IL-2 Treatment in Vivo on the Expansion of
Effector Cell Populations in CD44 WT, CD44v6-v7 KO, and
CD44v7 KO Mice—We examined whether the reduction in the
level of VLS seen in CD44v7 KO and CD44v6-v7 KO mice when
compared with CD44 WT mice resulted from altered expansion
of the effector cells. To this end, CD44 WT, CD44v7 KO, and
CD44v6-v7 KO mice were treated with IL-2, as described
above. After the final injection of IL-2 on day 4, spleens were
harvested, cellularity was determined and the cells were
stained for the expression of CD4, CD8, and combined CD3 and
NK1.1. IL-2 treatment caused marked and somewhat similar
increase in total cellularity of the spleen, in all groups of mice,
when compared with the PBS-treated controls (Table II). Fur-
thermore, IL-2 treatment led to an increase in the percentage
and total number of CD8 and a consequent decrease in the
percentage of CD4 cells (Table II). Similar results were seen
in the CD44v7 KO and CD44v6-v7 KO mice, indicating that the
reduction in VLS seen in these mice was not the result of an
alteration in the expansion of CD8 cells in vivo. When the
effect of IL-2 treatment on NK (CD3NK1.1) and NK-T
(CD3NK1.1) cells was investigated, it was observed that
IL-2 caused a similar increase in the percentage and total
number (Fig. 4, Table II) of NK and NK-T cells in CD44 WT,
CD44v6-v7 KO, and CD44v7 KO mice. Together these results
suggested that treatment with IL-2 led to the expansion of
CD8 T cells, NK cells, and NK-T cells and that this expansion
was not altered in CD44v7 KO or CD44v6-v7 KO mice when
compared with CD44 WT mice.
IL-2-activated Killer Cell Activity against Endothelial Cell
(EC) Targets Is Reduced in CD44v6-v7 and CD44v7 KO Mice in
Vitro and in Vivo—IL-2-activated cytotoxic cells can kill EC
and induce VLS (33). Therefore, we compared the ability of
splenocytes from IL-2-treated CD44 WT, CD44v6-v7 KO, and
CD44v7 KO mice to lyse TME, a well characterized endothelial
cell line. To this end, CD44 WT, CD44v6-v7 KO, and CD44v7
KO mice were treated with IL-2 for 4 days, as described above.
The splenocytes were harvested and tested for cytotoxicity
against EC targets using a standard chromium release assay
(Fig. 5A). The results demonstrated that splenocytes from
CD44 WT mice caused significant lysis of EC. However, the
lysis of the EC was greatly diminished in the cultures contain-
ing the CD44v6-v7 and CD44v7 KO splenocytes.
The decreased LAK activity of splenocytes from CD44v6-v7
and CD44v7 KO mice against EC was further confirmed by
experiments in which splenocytes from CD44 WT, CD44v6-v7
KO, and CD44v7 KO mice were cultured with high concentra-
tions of IL-2 (1000 units/ml) for 48 h in vitro and examined for
their ability to lyse TME EC, SVC3H fibroblasts, and P815
tumor cells. The results showed that IL-2-activated cytotoxic
cells from CD44v6-v7 KO and CD44v7 KO mice exhibited de-
creased ability to kill EC when compared with the LAK cells
from the CD44 WT mice (Fig. 5B). The lytic activity was spe-
FIG. 2. VLS induction following IL-2 treatment in vivo. CD44
WT, CD44 KO, CD44v7 KO, and CD44v6-v7 KO mice were injected
intraperitoneally with 75,000 units of IL-2 alone 3 times daily for 3 days
and once on day 4 or with PBS. Two hours after the last injection with
IL-2, the mice were injected with 1% Evans blue, and VLS was studied
by determining the extravasation of Evans blue dye in the lungs. The
vertical bars represent the percentage of increase in VLS  S.E. follow-
ing IL-2 treatment compared with that in the PBS-treated controls as
described in ‘‘Materials and Methods.’’ Asterisks indicate statistically
significant difference when compared with the CD44 WT controls,
p  0.05.
FIG. 3. Histological studies of lungs following IL-2 administra-
tion. Lungs from CD44 WT mice treated with PBS (A) and lungs from
CD44 WT (B), CD44v6-v7 KO (C), and CD44v7 KO (D) mice treated
with IL-2 were harvested, preserved in 10% formalin solution, sec-
tioned, and stained with hematoxylin and eosin. Arrows indicate
perivascular infiltration, consisting mostly of lymphocytes. E, The level
of perivascular infiltration was determined by counting the number of
cells infiltrating a venule. The data depict the mean  S.E. of sections
from four individual mice.
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cific for endothelial cells, as the LAK cells were unable to cause
significant lysis of SVC3H fibroblasts bearing the same MHC
molecules as the TME EC (Fig. 5C). Interestingly, the ability of
the LAK cells from CD44v6-v7 KO and CD44v7 KO mice to lyse
the P815 tumor targets was not significantly affected when
compared with LAK cells from CD44 WT mice (Fig. 5D). To-
gether, these results suggested that the reduction in IL-2-
induced VLS in CD44v6-v7 KO and CD44v7 KO mice may be
the result of reduced EC killing.
Recently, it was shown that CD44-dependent cytolysis could
be distinguished from natural cytotoxicity according to the
sensitivity to inhibition by the PI 3-kinase inhibitor, wortman-
nin (24). More specifically, it was shown that CD44-dependent
cytolysis was highly sensitive to wortmannin inhibition,
whereas natural cytotoxicity was relatively resistant. There-
fore, we examined the effect of wortmannin (5 nM) treatment on
the ability of LAK cells to mediate lysis of EC as well as P815
tumor cells. The results demonstrated that the lysis of EC was
significantly inhibited by wortmannin, whereas the lysis of
P815 was generally unaffected (Fig. 5E). In addition, we exam-
ined the effect of the tyrosine kinase inhibitor, herbimycin (0.52
M), on LAK-mediated lysis of EC and P815. Exposure of LAK
cells to herbimycin effectively inhibited their ability to lyse EC
but not P815 tumor cells (Fig. 5E). Together, these results
suggest that both PI 3-kinase and tyrosine kinases play an
important role in LAK cell lysis of EC and that the mechanism
TABLE II
Effects of IL-2 on effector cell populations in vivo
Cellularitya
Splenocyte populationsb
CD4 CD8 CD3NK1.1 CD3NK1.1
cell no.  106/spleen
CD44 WT  PBS 131.8  8.2c 24.7 (32.6) 14.8 (19.5) 8.5 (11.2) 1.3 (1.7)
CD44 WT  IL-2 194.9  2.3 18.4 (35.9) 21.6 (42.1) 29.4 (57.3) 5.6 (10.9)
CD44v7 KO  PBS 98.7  3.0 28.6 (28.2) 11.2 (11.1) 8.5 (8.4) 0.7 (0.7)
CD44v7 KO  IL-2 192.2  10.4 15.9 (30.5) 21.4 (41.1) 24.21 (46.5) 2.8 (5.4)
CD44v6-v7 KO  PBS 85.1  5.3 24.7 (21.0) 15.0 (12.8) 11.35 (9.7) 1.2 (1.0)
CD44v6-v7 KO  IL-2 198.5  3.2 15.5 (30.8) 21.2 (42.1) 26.6 (52.8) 4.2 (8.3)
a Mice were treated with IL-2 (75,000 units/mouse three times daily for 4 days) or the vehicle. On day 4, the spleens were harvested and the total
cellularity was determined.
b Splenocyte subsets were determined using flow cytometry. The data represent the percentage of CD4 T cells, CD8 T cells, CD3NK1.1 cells,
and CD3NK1.1 cells in the spleens obtained from 3 mice. The numbers in parentheses represent the mean total cellularity  106 of each cell
population found in the spleens.
c Data represent mean  S.E. obtained from 3 mice.
FIG. 4. Expansion of NK and NK-T cells following IL-2 stimu-
lation in vivo. Splenocytes from PBS- and IL-2-treated CD44 WT and
CD44v7 KO mice were stained with PE-conjugated anti-CD3 mAbs and
FITC-conjugated anti-NK1.1 mAbs for 30 min and analyzed by a flow
cytometer. The percentage of positive cells is depicted in each quadrant.
FIG. 5. Cytolytic activity of IL-2-stimulated LAK cells. Spleno-
cytes from IL-2-treated CD44 WT, CD44v6-v7 KO, and CD44v7 KO
mice (A) or naive splenocytes from CD44 WT, CD44v6-v7 KO, and
CD44v7 KO mice cultured in vitro for 48 h with 1000 units/ml IL-2 (B)
were used as effector cells and were tested for cytolytic activity against
51Cr-labeled TME endothelial cell targets. Splenocytes cultured for 48 h
with 1000 units/ml IL-2 were used as effectors against 51Cr-labeled
-SVC3H fibroblast (C) or -P815 (D) target cells. E, the effects of wort-
mannin (5 nM) and herbimycin (0.52 M) on IL-2-induced LAK-medi-
ated killing of EC and P815 tumor targets (50:1, effector to target ratio).
LAK activity was determined using the 4-h 51Cr release assay. The data
indicate the mean percentage of cytotoxicity of triplicate cultures S.E.
Asterisk indicates statistically significant difference when compared
with the CD44 WT controls, p  0.05.
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of EC lysis by LAK cells is distinct from the mechanism of LAK
cell-mediated lysis of P815 tumor cells.
Lysis of EC following IL-2 Stimulation Is Mediated by
“CD44hi” LAK Cells—As shown previously (39) and in the cur-
rent study (Fig. 8, E–G), normal splenocytes constitutively
express lower levels of CD44 (CD44lo) and upon stimulation
with IL-2, a significant proportion of the cells up-regulate
CD44 (CD44hi). We examined whether the cytolytic activity
against EC was mediated by CD44lo and/or CD44hi cells and,
furthermore, whether the cytotoxicity exhibited by these sub-
populations was altered in CD44V7 KO mice. To this end,
splenocytes CD44 WT or CD44v7 KO mice were stimulated for
48 h with IL-2 (1000 units/ml) and stained with PE-conjugated
pan-anti-CD44 mAbs (IM7) and then sorted by FACS into
CD44lo and CD44hi populations. Fig. 6A depicts the results
from a typical cell sorting experiment. As seen from the left
panels, IL-2-activated splenocytes exhibited CD44lo and
CD44hi populations. After sorting the CD44lo and CD44hi cells,
these subsets were reanalyzed for CD44 expression. As seen
from Fig. 6A (middle and right panels), CD44hi cells expressed
mean fluorescence intensity of 146, whereas the CD44hi cells
exhibited mean fluorescence intensity of 941 in CD44 WT mice,
thereby confirming the purity of the subpopulations. Similar
results were obtained using splenocytes from CD44v7 KO mice.
Next, the CD44lo and CD44hi LAK cells from CD44 WT and
CD44v7 KO mice were tested for their ability to kill EC cell
target (Fig. 6B). The results showed that CD44hi cells from
CD44 WT mice exhibited marked cytolytic activity against EC
targets. In contrast, the CD44hi cells from CD44v7 KO mice
had dramatically reduced lytic activity against EC. Moreover,
CD44lo cells from both groups of mice had virtually no lytic
activity against EC. These data further established that IL-2-
induced expression of CD44v7 on LAK cells plays an important
role in EC killing.
Expression of CD44v7 on LAK Cells Plays an Important Role
in IL-2-induced EC Damage and VLS—To further corroborate
in vivo that CD44v7 expression on LAK cells plays a critical
role in VLS, we performed experiments in which splenocytes
from CD44 WT and CD44v7 KO mice were adoptively trans-
ferred into CD44 WT or CD44v7 KO recipient mice followed by
IL-2 treatment (Fig. 7A). The results demonstrated that trans-
fer of CD44 WT splenocytes into CD44 WT or CD44v7 KO mice
led to a significant increase in IL-2-induced VLS when com-
pared with the transfer of splenocytes from CD44v7 KO mice
into CD44 WT or CD44v7 KO mice. The importance of LAK cell
expression of CD44v7 was confirmed in a crisscross mixing
experiment. To this end, splenocytes from CD44 WT or CD44v7
KO mice were stimulated with IL-2 for 48 h. The LAK cells
were then stained with CFSE and then cultured with freshly
isolated lung EC from either CD44 WT or CD44v7 KO mice.
The lytic activity was determined following 4 h of culture by
staining the cells with propidium iodide. Cells staining nega-
tive for CFSE were gated, and the percentage of cells positive
for propidium iodide was calculated (Fig. 7B). The results dem-
onstrated that the percentage of EC lysed by LAK cells from
CD44 WT mice was significantly greater than the percentage of
EC targets lysed by LAK cells from CD44v7 KO mice, regard-
less of the expression of CD44v7 on the EC targets. Together,
these results suggested that the expression of CD44v7 on IL-
2-activated LAK cells plays an important role in mediating
EC lysis.
The Reduced Lytic Activity of LAK Cells from CD44v6-v7 KO
and CD44v7 KO Mice Is Not the Result of Alterations in Acti-
vation or Expression of Cytolytic Effector Molecules—Next, we
examined the possibility that the reduced IL-2-induced EC
damage seen in CD44v6-v7 KO and CD44v7 KO mice resulted
from decreased responsiveness to activation stimuli and/or be-
cause of a reduction in the expression of effector molecules
involved in the lytic activity of LAK cells. To this end, spleno-
cytes were cultured in the presence of IL-2 (Fig. 8A) or ConA
(Fig. 8B) for 48 h and the proliferative responsiveness was
measured. The results showed that splenocytes from the
CD44v6-v7 KO and CD44v7 KO mice responded to IL-2 or
ConA to the same extent as cells from CD44 WT mice. Similar
results were seen when the levels of CD69, an activation
marker, were measured using FACS analysis (Fig. 8C). These
results suggested that the reduced induction of VLS seen in the
CD44v6-v7 KO and CD44v7 KO mice was not the result of a
defect in the activation and proliferation of T cells from
these mice.
Increased levels of FasL, perforin, and TNF- play an impor-
tant role in the cytolytic activity of lymphocytes. Therefore, we
examined the expression of FasL, perforin and TNF- mRNA
in splenocytes following injection of PBS (control) or IL-2 in
vivo (Fig. 8D). Splenocytes from IL-2-treated CD44 WT,
CD44v6-v7 KO, and CD44v7 KO mice were found to express
increased levels of FasL when compared with PBS-treated
mice. Such an increase was similar in all three groups of mice.
IL-2 treatment caused a modest or no significant increase in
FIG. 6. Cytolytic activity of IL-2-activated splenocytes express-
ing high or low levels of CD44. Splenocytes from CD44 WT and
CD44v7 KO mice were stimulated with IL-2 (1000 units/ml) for 48 h.
The cells were then stained with PE-conjugated anti-CD44 mAbs and
sorted according to the level of CD44 expression. Panel A depicts the
expression levels of CD44 on IL-2-activated splenocytes before (Unsort-
ed) and after sorting (CD44lo and CD44hi). B, CD44hi and CD44lo spleno-
cytes from CD44 WT and CD44v7 KO mice were then tested for their
ability to lyse EC targets. LAK activity was determined using the 4-h
51Cr release assay. The data indicate the mean percentage of cytotox-
icity of triplicate cultures  S.E.
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the levels of perforin and TNF- mRNA in all three groups of
mice when compared with their PBS-treated counterparts.
Moreover, the levels of mRNA for perforin and TNF- were
similar in these three groups of mice treated with PBS or IL-2.
These results suggested that the reduced IL-2-induced VLS
and decreased lytic activity against EC seen in the CD44v6-v7
KO and CD444v7 KO mice did not result from reduced expres-
sion of cytolytic effector molecules.
Previous studies from our laboratory have shown that IL-2
treatment in vivo leads to increased expression of CD44 (9, 10).
Because the CD44v6-v7 and CD44v7 isoforms have been spe-
cifically deleted from the CD44v6-v7 KO and CD44v7 KO mice,
respectively, IL-2 stimulation should still lead to up-regulation
of remaining CD44 isoforms in these mice. Therefore, we ex-
amined whether the expression of CD44 was increased in
CD44v6-v7 KO and CD44v7 KO mice following IL-2 treatment.
CD44 WT, CD44v6-v7 KO, and CD44v7 KO mice were treated
for 4 days with IL-2 as described above. After which, the
splenocytes were analyzed for the expression of CD44 using a
pan antibody, IM7, which recognizes all isoforms of CD44 (Fig.
8E). The results showed that there was a significant increase in
the expression of CD44 in splenocytes from CD44 WT,
CD44v6-v7 KO, and CD44v7 KO mice following IL-2 treatment
in vivo, which was similar in all three groups of mice.
It is possible that the increased expression of CD44 on
splenocytes seen after IL-2 treatment in vivo may result from
migration of CD44 cells into the spleen rather than direct
activation of LAK cells. To address this, the effect of in vitro
IL-2 stimulation of splenocytes on the expression of CD44 iso-
forms containing the CD44v6 and CD44v7 exons was deter-
mined. To this end, splenocytes from CD44 WT and CD44v7
KO mice were stimulated for 48 h with 1000 units/ml IL-2. As
shown in Fig. 8F, stimulation with IL-2 in vitro caused an
increase in the expression CD44 isoforms containing the v6 and
v7 exons in splenocytes from CD44 WT mice. In comparison,
CD44 isoforms containing the v6 exon but not the v7 exon were
increased in splenocytes from CD44v7 KO mice. It should be
noted that the PBS-injected control mice failed to exhibit
CD44v6-v7 when directly tested (Fig. 1A), whereas the in vitro
control cultures of splenocytes incubated with medium alone
showed CD44v6-v7 expression. This can be explained by the
fact that in vitro culture conditions provide fetal calf serum and
other growth factors, which may activate some splenocytes to
express CD44v6-v7. Fig. 8G depicts the level of CD44 protein
expression of splenocytes from CD44 WT or CD44v7 KO mice
following 48-h culture of splenocytes with or without IL-2 in
vitro. CD44 expression was determined by staining splenocytes
with anti-CD44 mAbs (IM7), which recognizes both the stand-
ard form and all isoforms of CD44, followed by flow cytometric
analysis. The results showed that, following stimulation with
IL-2 in vitro, CD44 expression increased to a similar extent in
splenocytes from CD44 WT and CD44v7 KO mice, as indicated
by an increase in the mean fluorescence intensity.
Adherence and Cell Aggregation between EC and IL-2-in-
duced LAK Cells from CD44 WT and CD44v7 KO Mice in
Vitro—We next examined the possibility that the absence of
CD44v7 on IL-2-activated lymphocytes leads to a reduction in
their adherence to EC. To quantify the adhesion, LAK cells
from CD44 WT and CD44v7 KO mice were labeled with
[3H]thymidine and cultured with confluent layers of EC for 2 h.
The percentage of cells adhering to the EC was determined as
described under “Materials and Methods.” The results showed
that there was significant adhesion between EC and IL-2-
activated splenocytes from the CD44 WT mice (Fig. 9A). In
contrast, the IL-2-activated splenocytes from the CD44v7 KO
mice showed a reduced capacity to adhere to the EC. The effect
on adherence of LAK cells to EC was further demonstrated
using PKH-labeled LAK cells and CFSE-labeled EC (Fig. 9C).
In this experiment, increased numbers of LAK cells from CD44
WT mice bound to the EC when compared with the CD44v7
KO mice.
Because TME is an established cell line and inasmuch as EC
from the lungs may be unique, we examined whether IL-2-
activated splenocytes from CD44v7 KO mice had a reduced
capacity to form conjugates with freshly isolated primary lung
EC. To this end, we isolated EC from TIE2-GFP transgenic
mice in which GFP is expressed only by EC. The GFP EC were
mixed with PKH-labeled LAK cells, and cell aggregation was
studied. Cell aggregation was quantified by determining the
percentage of endothelial cells per field conjugated to at least
one LAK cell, using the formula described under “Materials
and Methods.” The data depicted in Fig. 9B represent the
mean  S.E. from 10 randomly chosen fields. Representative
images of LAK cells from either CD44 WT or CD44v7 KO mice
FIG. 7. Expression of CD44v7 on LAK cells plays an important role in IL-2-induced EC damage and VLS. A, splenocytes (5 107) from
CD44 WT mice or CD44v7 KO mice were adoptively transferred into CD44 WT or CD44v7 KO recipient mice. The mice were then treated with IL-2
three times daily for 3 days and once on day 4. Two hours after the last injection of IL-2, the mice were injected with 1% Evans blue dye and VLS
was studied by quantifying the extravasation of dye in the lungs. B, splenocytes from CD44 WT and CD44v7 KO mice were stimulated for 48 h
with 1000 units OF IL-2. The LAK cells were stained with CFSE and then cultured for 4 h with freshly isolated EC from either CD44 WT or CD44v7
KO mice. The cultures were stained with propidium iodide, and the percentage of lysis of EC was assessed by determining the percentage of
CFSE-negative/PI-positive cells. Asterisk indicates statistically significant difference when compared with the CD44 WT controls, p  0.05.
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adhering to TIE2-GFP lung EC are shown in Fig. 9D. These
results further confirmed that the level of cell aggregation
between LAK cells and freshly isolated lung EC was signifi-
cantly greater in CD44 WT mice when compared with CD44v7
KO mice.
The Effect of Anti-CD44v7 mAbs on LAK Cell Adherence to
and Lysis of EC in Vitro and IL-2-induced VLS in Vivo—To
further confirm the involvement of CD44v7 in IL-2-induced EC
damage and VLS, we examined the effect of anti-CD44v7 mAbs
on LAK cell adherence to and killing of EC. First, we examined
the effect of anti-CD44v7 mAbs on the ability of LAK cells to
adhere to EC. To this end, [3H]thymidine-labeled LAK cells 
soluble anti-CD44v7 mAbs or [3H]thymidine-labeled LAK cells
soluble isotype control antibodies were added to plates coated
with EC (Fig. 10A). The percentage of LAK cells adhering to the
EC was determined 2 h later as described under “Materials and
Methods.” The results showed that anti-CD44v7 mAbs effec-
tively blocked the adherence of LAK cells to EC. Next, we
examined the effect of anti-CD44v7 mAbs on the lysis of EC by
LAK cells. To this end, LAK cells were cultured with anti-
CD44v7 or isotype control mAbs along with 51Cr-labeled EC or
P815 tumor cells and cytotoxicity was studied using the 4-h
chromium release assay. The results showed that incubation
with anti-CD44v7 mAbs significantly reduced LAK cell lysis of
EC (Fig. 10B). Interestingly, incubation with anti-CD44v7
mAbs had no effect on the killing of P815 tumor cells. Finally,
we examined whether treatment with anti-CD44v7 mAbs
would have any effect on the level of IL-2-induced VLS (Fig.
10C). To this end, mice were injected for 4 days with IL-2. In
addition, the mice were treated daily with isotype control mAbs
FIG. 8. Reduced lytic activity of LAK cells from CD44v6-v7 KO
and CD44v7 KO mice is not the result of alteration in prolifer-
ation/activation or expression of effector molecules such as Fas
ligand, perforin, or TNF-. Splenocytes from CD44 WT and CD44v7
KO mice were stimulated for 48 h with interleukin-2 (1000 units/ml) (A)
or ConA (5 g/ml) (B). During the final 8 h of culture, the cells were
pulsed with 2 Ci of [3H]thymidine. Thymidine incorporation was de-
termined by -scintillation counting. The data represent mean S.E. of
triplicate wells. C, activation was further assessed by examining the
effect of ConA and IL-2 on CD69 expression by FACS analysis. D,
detection of Fas ligand, perforin, and TNF- mRNA in splenocytes from
PBS- or IL-2-treated mice. Total RNA was isolated from splenocytes of
PBS- or IL-2- injected mice as described in Fig. 1. mRNA was reverse
transcribed and amplified by PCR with primers specific for Fas ligand,
perforin, TNF-, and -actin. Lane 1, CD44 WT  PBS; lane 2, CD44
WT  IL-2; lane 3, CD44v6-v7 KO  PBS; lane 4, CD44v6-v7  IL-2;
lane 5, CD44v7 KO  PBS; lane 6, CD44v7 KO  IL-2. A photograph of
ethidium bromide-stained amplicons is depicted. E, the expression of
CD44 on splenocytes from CD44 WT, CD44 KO, CD44v6-v7 KO, and
CD44v7 KO mice following activation with IL-2 in vivo was determined
using FACS analysis. F, the expression of CD44 isoform mRNA con-
taining the v6 or v7 exon in splenocytes unstimulated or stimulated
with IL-2 (1000 units/ml) for 48 h was determined by RT-PCR analysis.
G, the expression of CD44 on splenocytes from CD44 WT and CD44v7
KO mice following activation with IL-2 in vitro was determined using
FACS analysis.
FIG. 9. Adherence and cell aggregation between endothelial
cells and IL-2-induced LAK cells from CD44 WT and CD44v7 KO
mice in vitro. A, [3H]thymidine-labeled LAK cells were cultured for 2 h
in plates containing TME endothelial cells. LAK cells not adhering to
TME cells were removed by gently washing with medium. Adherent
cells were quantified by measuring the [3H]thymidine activity and
compared with the [3H]thymidine activity of cells removed from wells
without TME cells (total activity). The percentage of LAK cells adhering
to the TME was determined as described under “Materials and Meth-
ods.” Asterisk indicates statistically significant difference when com-
pared with the CD44 WT splenocytes, p  0.05. C, in parallel studies,
PKH-labeled LAK cells (red) were cultured with CFSE-labeled TME
cells (green). Cell aggregation was visualized using a fluorescent micro-
scope (original magnification,  400). B, cell aggregation between LAK
cells and freshly isolated endothelial cells was quantified by counting
the percentage of endothelial cells from TIE2-GFP mice conjugated to at
least one LAK cell per field. The data depicted represent the mean 
S.E. from 10 randomly chosen fields. Asterisk indicates statistically
significant difference when compared with the CD44 WT mice, p 0.05.
D, cell aggregation was visualized by centrifuging PKH-labeled LAK
cells (yellow) with endothelial cell (green) isolated from TIE2-GFP mice
as described under “Materials and Methods.” Cell aggregation was
visualized using a fluorescent microscope (original magnification,
400).
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or anti-CD44v7 mAbs. The results from this experiment dem-
onstrated that treatment with anti-CD44v7 mAbs significantly
reduced the level of IL-2-induced VLS when compared with the
isotype control mAb-treated group. Together, these results sug-
gested that anti-CD44v7 mAbs effectively blocked LAK cell
adherence to and lysis of EC and, furthermore, markedly re-
duced IL-2-induced VLS in vivo.
Role of CD44-HA Interactions in CD44 WT and CD44v7 KO
Mice—HA is one of the major ligands for CD44. Previous re-
ports demonstrated that activation of lymphocytes leads to
increased HA binding (40, 41). It was possible that deletion of
v6 and v7 exon products resulted in altered binding to HA.
Therefore, we examined whether splenocytes from CD44 WT,
CD44 KO, or CD44v7 KO mice exhibited altered ability to bind
to HA. Following stimulation with IL-2 in vitro, splenocytes
from CD44 WT and CD44v7 KO mice showed significant and
comparable binding to HA-coated plates (Fig. 11A). In contrast,
splenocytes from CD44 KO mice did not show any detectable
binding to HA. Unactivated splenocytes, regardless of the ex-
pression of CD44, were not able to bind HA-coated plates (data
not shown). In addition, we examined the effect of pretreat-
ment of LAK cells and/or EC cells with hyaluronidase on the
LAK-mediated killing of EC (Fig. 11B). The results showed
that pretreatment of either LAK cells or EC with hyaluroni-
dase had no significant effect on the ability of IL-2-stimulated
cytotoxic cells to kill EC targets. Together, these results sug-
gested that CD44v7 was not critical for the binding of IL-2-
activated splenocytes to HA.
Lysis of Endothelial Cells by LAK Cells Is Suppressed by
Addition of Soluble or Enzymatic Cleavage of CD44v7 Li-
gands—In this study we demonstrated that the ability of
splenocytes from CD44v7 KO mice to bind HA was similar to
that seen using cells from CD44 WT mice (Fig. 11A), thereby
suggesting that the absence of CD44v7 did not alter HA bind-
ing. The expression of CD44v6-v7 has been shown to facilitate
the binding to other glycosaminoglycans including chondroitin
sulfate, heparin, and heparin sulfate (42). Therefore, we exam-
ined the effect of soluble chondroitin sulfate and heparin on
IL-2-stimulated LAK-mediated lysis of EC and P815 tumor
cells. The results showed that addition of soluble chondroitin
sulfate A, B, and C and heparin caused significant inhibition in
the lysis of EC (Fig. 12A) without causing any decrease in the
lysis of P815 tumor cells (Fig. 12B). These data were confirmed
by the fact that addition of enzymes specific for chondroitin
sulfate and heparin, significantly reduced LAK cell-mediated
FIG. 10. Anti-CD44v7 mAbs inhibit LAK cell adherence to and
lysis of endothelial cells in vitro as well as the induction of IL-2-
induced VLS in vivo. A, the effect of anti-CD44v7 mAbs on the adher-
ence of LAK cells to TME endothelial cells was determined by culturing
[3H]thymidine-labeled LAK cells  anti-CD44v7 mAbs or isotype control
mAbs on plates coated with TME cells. The percentage of LAK cells
adhering to the TME cells was determined 2 h later as described under
“Materials and Methods.” B, to examine the effect of anti-CD44v7 mAbs
on the lysis of TME cells, LAK cells were cultured with anti-CD44v7 mAbs
(10 g/ml) or isotype control mAbs (10 g/ml) and directed against 51Cr-
labeled TME or P815 tumor cells in a 4-h chromium release assay. The
data indicate the mean percentage of cytotoxicity of triplicate cultures 
S.E. C, the effect of anti-CD44v7 mAbs on IL-2-induced VLS in vivo was
determined by injecting mice for 4 days with IL-2, as described under
“Materials and Methods,” and treating the mice with anti-CD44v7 mAbs
(100 g/mouse intraperitoneally) or isotype control mAbs (100 g/mouse
intraperitoneally) once a day for 4 days. Vascular leak was determined as
described above. Asterisk indicates statistically significant difference
when compared with the controls, p  0.05.
FIG. 11. The role of CD44-HA interactions in CD44 WT and
CD44v7 KO mice. A, to determine the ability of IL-2-stimulated
splenocytes to bind to HA-coated plates, the splenocytes were labeled
for 4 h with [3H]thymidine (5 Ci/ml). The labeled splenocytes (105/
well) were added to each well of HA-coated plates and incubated for 1 h
at 37 °C. Non-adherent cells were removed by gently pipetting with
PBS. The percentage of cells adhering to the plate was determined
using the formula described under “Materials and Methods.” B, the
effect of pretreatment of either LAK cells or EC with hyaluronidase on
the LAK-mediated killing of EC cells was determined. Briefly, IL-2-
stimulated splenocytes from CD44 WT mice and EC were untreated
(control) or pretreated for 1 h at 37 °C with hyaluronidase (100 rTRU/
ml). After treatment, the cells were washed and EC lysis was deter-
mined using the 4-h 51Cr release assay. The data represent an effector
to target ratio of 25 and indicate the mean percentage of cytotoxicity of
triplicate cultures  S.E.
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lysis of EC targets (Fig. 12C) without significantly decreasing
the lysis of the P815 tumor cells (Fig. 12D). Together these data
suggested that interaction between CD44v6-v7 and certain
glycosaminoglycans may play a significant role in LAK cell-
mediated lysis of EC.
DISCUSSION
EC damage is widely reported in a number of pathological
diseases including infections, autoimmunity, transplantation,
graft-versus-host disease, and following immunotherapy with
cytokines and immunotoxins. Previous work from our labora-
tory implicated CD44 expressed by cytolytic lymphocytes in
IL-2-induced EC injury leading to VLS (10). However, the
nature of specific isoforms of CD44 involved was unclear.
Therefore, the current study was designed to determine which
CD44 isoforms were involved in VLS. We demonstrated that,
following IL-2 administration in vivo, the expression of CD44v7
and CD44v6-v7 was up-regulated. In addition, we demon-
strated that IL-2-induced VLS was markedly abrogated in mice
lacking CD44v6-v7 and CD44v7. This abrogation was not the
result of decreased activation or expansion of effector cell pop-
ulation but was the result of reduced lytic capabilities of lym-
phocytes lacking the CD44v6-v7 or CD44v7 isoforms because of
reduced adhesion to EC. Furthermore, the LAK cell binding to
and lysis of EC in vitro and IL-2-induced VLS in vivo was
blocked by anti-CD44v7 mAbs.
CD44 has been implicated in a number of immunological
processes including lymphopoiesis, lymphocyte activation,
homing, and leukocyte rolling and extravasation into sites of
inflammation (19). Studies have shown that interactions be-
tween CD44 and HA are important in the initial attachment
and rolling of lymphocytes along the endothelium (43). How-
ever, evidence from this study suggests that CD44v7 may not
be critical for the interaction with HA or for lymphocyte ex-
travasation into the lungs. IL-2-activated splenocytes from
CD44 WT or CD44v7 KO mice showed similar levels of binding
to HA; furthermore, pretreatment of LAK cells or EC with
hyaluronidase did not affect the ability of the LAK cells to kill
EC. Finally, we noted that infiltration of lymphocytes into the
lungs following IL-2 treatment was not significantly altered in
CD44v6-v7 KO or CD44v7 KO mice. These data are consistent
with our earlier findings that, in IL-2-induced VLS or ConA-
induced hepatitis, the infiltration of mononuclear cells in the
lungs or liver is not significantly altered in CD44 KO mice,
which lack the entire CD44 gene (10, 44). Moreover, the bind-
ing of CD44 to HA and other ligands is tightly regulated and
depends on the status of the CD44 molecule. In fact, most CD44
molecules are unable to bind HA but must be induced to bind to
HA. Some factors that may be involved in inducing CD44
binding to HA include increased expression, receptor cluster-
ing, glycosylation, and sulfation (45). In addition, evidence
suggests that the expression of CD44 isoforms was not neces-
sary for binding of lymphocytes to HA on EC (43). Interestingly,
it has been shown that the expression of CD44 isoforms con-
taining v6 and v7 led to increased binding to other glycosami-
noglycans including chondroitin sulfate, heparin, and heparin
sulfate (42). EC express such glycosaminoglycans (46), thereby
suggesting the possibility that the increased expression of
CD44v6-v7 on IL-2-activated lymphocytes may lead to in-
creased binding to EC. The consequence of such increased
binding could be the induction of cytotoxicity of EC resulting in
vascular leak as shown in the current study. In fact, increased
CD44-mediated binding of mononuclear leukocytes to target
cells has been implicated in other diseases such as inflamma-
tory bowel disease (47).
Previous studies have demonstrated that EC also express
CD44 (43, 48). Thus, we cannot entirely exclude the possibility
that the expression of CD44v7 on EC plays some role in IL-2-
induced VLS. Nevertheless, using adoptive transfer experi-
ments, we noted that lymphocytes transferred from CD44 WT
into CD44v7 KO mice caused higher levels of IL-2-induced VLS
when compared with transfer of CD44v7 KO lymphocytes into
CD44v7 KO mice. Moreover, results from crisscross mixing
experiments demonstrated that expression of CD44v7 on LAK
cells is important for killing either CD44 WT EC or CD44v7 KO
EC. Together, these data suggested that expression of CD44v7
on IL-2-stimulated LAK cells, rather than EC, plays an impor-
tant role in the induction of VLS.
We demonstrated that treatment with IL-2 in vivo led to the
expansion of CD8 T cells, NK cells, and NK-T cells in both
CD44 WT and CD44 KO mice. Additionally, we showed that
splenocytes activated in vitro or in vivo with IL-2 efficiently
killed EC targets while leaving fibroblast targets unharmed.
The fact that both the fibroblast and EC used in this study had
the same MHC would suggest that the killing of the endothelial
cells was MHC-unrestricted and specific for EC. These data
also suggested that the induction of vascular leak is mediated
by IL-2-activated LAK cells. This is further supported by ear-
lier studies showing that IL-2-activated LAK cells can adhere
to and kill EC targets (49). In addition, the toxic side effects
induced by IL-2 were significantly reduced following NK cell
depletion (50). In addition, previous studies from our labora-
tory showed that mice deficient in FasL or perforin had mark-
edly decreased VLS (9).
In a study by Baluna et al. (51), it was reported that IL-2
coupled to mouse IgG could bind directly to and cause damage
to EC. However, in the current study we did not see any direct
toxicity to endothelial cell cultures following exposure to IL-2
FIG. 12. Lysis of endothelial cells by LAK cells is suppressed by
addition of soluble or enzymatic cleavage of CD44v7 ligands. To
determine the effect of soluble CD44v7 ligand, LAK cells were directed
against endothelial cell (A) or P815 (B) in the presence of 0.5 mg/ml
various glycosaminoglycans. To determine the effect of enzymatic cleav-
age of CD44v7 specific glycosaminoglycans, LAK cells were cultured
with endothelial cells (C) or P815 (D) in the presence of various glyco-
saminoglycan enzymes. The LAK activity was determined using the 4-h
51Cr release assay. The data indicate the mean percentage of cytotox-
icity of triplicate cultures  S.E. Asterisk indicates a statistically sig-
nificant decrease when compared with the controls, p  0.05.
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in vitro (data not shown). This apparent discrepancy could be
the result of differences in experimental set-up. In the study by
Baluna et al., the presence of mouse IgG was necessary for the
induction of IL-2-mediated EC damage. In our experiments
examining the direct toxic effects of IL-2 on EC, mouse IgG was
not added. In addition, studies suggest that exposure of EC to
IL-2 does not affect the expression of a number of molecules
involved in the adhesion between lymphocytes and EC. For
example, exposure of EC to IL-2 had no direct effect on the
expression of hyaluronan, P-selectin, E-selectin, ICAM-1,
ICAM-2, VCAM-1, and PECAM-1 (52, 53). The effect of IL-2 on
the EC expression of heparin, heparin sulfate, chondroitin sul-
fate, and other CD44 ligands remains to be fully elucidated.
Together, these data suggest that IL-2 acts primarily on the
lymphocyte population leading to increased adherence to and
damage of EC.
Previously, we demonstrated that Fas ligand and perforin
play an important role in the induction of vascular leak (9).
This work suggested that blocking perforin or Fas ligand may
reduce IL-2-induced EC damage and vascular leak, thereby
facilitating tumor immunotherapy. However, because perforin
and Fas ligand play an important role in lymphocyte killing of
tumors, blocking perforin and/or Fas ligand may also decrease
the efficacy of IL-2 therapy in the treatment of cancers. This is
supported by our findings of reduced killing of YAC-1 tumor
targets in gld and perforin KO mice (9). In contrast, in the
current study, we noted that blocking CD44v7 decreased the
killing of EC but not P815 tumor cells. Therefore, targeting
CD44 isoforms may offer an alternate and effective approach to
reducing VLS without affecting tumor killing.
We and others have shown that ligation of CD44 can signal
the induction of cytolytic activity in CTL and NK cells (20, 24).
However, little is known about the natural targets and/or the
ligands on target cells responsible for facilitating CD44-medi-
ated lysis. In this report we demonstrated that CD44v7 expres-
sion on LAK cells plays an important and specific role in the
injury to EC, and that this injury was mediated, at least in
part, by interactions with various glycosaminoglycans such as
chondroitin sulfate, and heparin. Previously, Sconocchia et al.
(24) demonstrated that PI 3-kinase and tyrosine kinase played
a role in CD44-directed lysis and that CD44-directed lysis could
be distinguished from natural cytotoxic activities of LAK cells
by the level of sensitivity to inhibition by wortmannin. In the
current study, we demonstrated that the lysis of EC but not
P815 cells was inhibited by anti-CD44v7 mAbs and that lysis of
EC but not P815 tumor cells was highly sensitive to treatment
with the PI 3-kinase inhibitor wortmannin and the tyrosine
kinase inhibitor herbimycin. Taken together, our study sug-
gests that the mechanisms of CD44v7-mediated lysis of EC
involves PI 3-kinase and tyrosine kinases and that the lysis of
EC and P815 tumor cells may be mediated by different and
distinct CD44lo and CD44hi pathways.
In the current study we observed that activation of spleno-
cytes with IL-2 up-regulates CD44 expression. Interestingly,
when we separated CD44lo and CD44hi cells from the activated
population, only CD44hi but not CD44lo cells had the potential
to kill EC. These findings are highly significant because it may
be possible to isolate such cells from tumor-bearing or immu-
nized host and be used for immunotherapy. Alternatively, it is
possible to target such cells with antibodies or fusion proteins
to cause their depletion in vivo, as a treatment modality to
prevent transplant rejection, graft-versus-host diseases, aller-
gies, etc.
In conclusion, this study demonstrates for the first time that
CD44v7 plays a critical role in EC injury and vascular leak
caused by IL-2. CD44v7 deficiency does not affect the activa-
tion, Fas ligand, and perforin expression or the migration of
LAK cells. In addition, we observed that LAK cells from
CD44v7 KO mice are able to kill P815 tumor targets to the
same extent as LAK cells from CD44 WT mice. Therefore, by
blocking the interaction between CD44v7 and the appropriate
ligands on the EC, such as by using anti-CD44v7 antibodies or
siRNAs directed against CD44v7, it may be possible to reduce
IL-2-induced vascular damage without affecting the antitumor
efficacy of IL-2 therapy. Patients with metastatic disease have
poor prognosis and a 5-year survival rate of less than 10% (54).
High dose IL-2 therapy has a response rate of up to 30% in
patients with metastatic melanoma, renal cell carcinoma, and
non-Hodgkins lymphoma (55, 56). Thus, to date, the best sys-
temic therapy for treating metastatic disease is high dose IL-2.
Our studies shed new light not only in understanding the basic
mechanisms involved in the interactions between LAK cells
and EC but also provide useful information in improving im-
munotherapy of cancer using IL-2.
REFERENCES
1. Doherty, P. C., Allan, J. E., Lynch, F., and Ceredig, R. (1990) Immunol. Today
11, 55–59
2. Tsukada, N., Matsuda, M., Miyagi, K., and Yanagisawa, N. (1993) J. Neurol.
Sci. 117, 140–147
3. Moyer, C. F., and Reinisch, C. L. (1984) Am. J. Pathol. 117, 380–390
4. McCluskey, R. T., and Fienberg, R. (1983) Hum. Pathol. 14, 305–315
5. Hewicker, M., and Trautwein, G. (1987) Lab. Anim. 21, 335–341
6. Baluna, R., and Vitetta, E. S. (1997) Immunopharmacology 37, 117–132
7. Nakajima, T., Schulte, S., Warrington, K. J., Kopecky, S. L., Frye, R. L.,
Goronzy, J. J., and Weyand, C. M. (2002) Circulation 105, 570–575
8. Yoneda, O., Imai, T., Goda, S., Inoue, H., Yamauchi, A., Okazaki, T., Imai, H.,
Yoshie, O., Bloom, E. T., Domae, N., and Umehara, H. (2000) J. Immunol.
164, 4055–4062
9. Rafi, A. Q., Zeytun, A., Bradley, M. J., Sponenberg, D. P., Grayson, R. L.,
Nagarkatti, M., and Nagarkatti, P. S. (1998) J. Immunol. 161, 3077–3086
10. Rafi-Janajreh, A. Q., Chen, D., Schmits, R., Mak, T. W., Grayson, R. L.,
Sponenberg, D. P., Nagarkatti, M., and Nagarkatti, P. S. (1999) J. Immu-
nol. 163, 1619–1627
11. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E.,
Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T.,
et al. (1985) N. Engl. J. Med. 313, 1485–1492
12. Rosenberg, S. A., Mule, J. J., Spiess, P. J., Reichert, C. M., and Schwarz, S. L.
(1985) J. Exp. Med. 161, 1169–1188
13. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., and Louie,
A. C. (1995) J. Clin. Oncol. 13, 688–696
14. Jacobson, E. L., Pilaro, F., and Smith, K. A. (1996) Proc. Natl. Acad. Sci.
U. S. A. 93, 10405–10410
15. Bechard, D. E., Gudas, S. A., Sholley, M. M., Grant, A. J., Merchant, R. E.,
Fairman, R. P., Fowler, A. A., and Glauser, F. L. (1989) Am. J. Med. Sci.
298, 28–33
16. Vial, T., and Descotes, J. (1995) Drug Saf. 13, 371–406
17. Christ, O., Gunthert, U., Haas, R., and Zoller, M. (2001) J. Leukocyte Biol. 69,
343–352
18. Lesley, J., Hyman, R., and Kincade, P. W. (1993) Adv. Immunol. 54, 271–335
19. Turley, E. A., Noble, P. W., and Bourguignon, L. Y. (2002) J. Biol. Chem. 277,
4589–4592
20. Rafi-Janajreh, A. Q., Nagarkatti, P. S., and Nagarkatti, M. (1998) Front.
Biosci. 3, D665–71
21. Seth, A., Gote, L., Nagarkatti, M., and Nagarkatti, P. S. (1991) Proc. Natl.
Acad. Sci. U. S. A. 88, 7877–7881
22. Hammond, D. M., Nagarkatti, P. S., Gote, L. R., Seth, A., Hassuneh, M. R., and
Nagarkatti, M. (1993) J. Exp. Med. 178, 2225–2230
23. Galandrini, R., De Maria, R., Piccoli, M., Frati, L., and Santoni, A. (1994)
J. Immunol. 153, 4399–4407
24. Sconocchia, G., Titus, J. A., and Segal, D. M. (1997) Blood 90, 716–725
25. Matsumoto, G., Nghiem, M. P., Nozaki, N., Schmits, R., and Penninger, J. M.
(1998) J. Immunol. 160, 5781–5789
26. Goodison, S., Urquidi, V., and Tarin, D. (1999) Mol. Pathol. 52, 189–196
27. van Weering, D. H., Baas, P. D., and Bos, J. L. (1993) PCR Methods Appl. 3,
100–106
28. Seiter, S., Schmidt, D. S., and Zoller, M. (2000) Int. Immunol. 12, 37–49
29. Van Driel, M., Gunthert, U., van Kessel, A. C., Joling, P., Stauder, R., Lok-
horst, H. M., and Bloem, A. C. (2002) Leukemia 16, 135–143
30. Wittig, B. M., Johansson, B., Zoller, M., Schwarzler, C., and Gunthert, U.
(2000) J. Exp. Med. 191, 2053–2064
31. Schmits, R., Filmus, J., Gerwin, N., Senaldi, G., Kiefer, F., Kundig, T., Wake-
ham, A., Shahinian, A., Catzavelos, C., Rak, J., Furlonger, C., Zakarian, A.,
Simard, J. J., Ohashi, P. S., Paige, C. J., Gutierrez-Ramos, J. C., and Mak,
T. W. (1997) Blood 90, 2217–2233
32. Motoike, T., Loughna, S., Perens, E., Roman, B. L., Liao, W., Chau, T. C.,
Richardson, C. D., Kawate, T., Kuno, J., Weinstein, B. M., Stainier, D. Y.,
and Sato, T. N. (2000) Genesis 28, 75–81
33. Hammond-McKibben, D. M., Seth, A., Nagarkatti, P. S., and Nagarkatti, M.
(1995) Int. J. Cancer 60, 828–836
34. Wittig, B., Schwarzler, C., Fohr, N., Gunthert, U., and Zoller, M. (1998)
J. Immunol. 161, 1069–1073
The Role of CD44v7 in LAK-mediated Endothelial Cell Damage 43829
35. Mustafa, A., McKallip, R. J., Fisher, M., Duncan, R., Nagarkatti, P. S., and
Nagarkatti, M. (2002) J. Immunother. 25, 476–488
36. Udaka, K. (1970) Proc. Soc. Exp. Biol. Med. 133, 1384
37. Li, L., Elliott, J. F., and Mosmann, T. R. (1994) J. Immunol. 153, 3967–3978
38. Marelli-Berg, F. M., Peek, E., Lidington, E. A., Stauss, H. J., and Lechler, R. I.
(2000) J. Immunol. Methods 244, 205–215
39. McKallip, R. J., Do, Y., Fisher, M. T., Robertson, J. L., Nagarkatti, P. S., and
Nagarkatti, M. (2002) Int. Immunol. 14, 1015–1026
40. Liu, D., Zhang, D., Mori, H., and Sy, M. S. (1996) Cell. Immunol. 174, 73–83
41. Lesley, J., and Hyman, R. (1992) Eur. J. Immunol. 22, 2719–2723
42. Sleeman, J. P., Kondo, K., Moll, J., Ponta, H., and Herrlich, P. (1997) J. Biol.
Chem. 272, 31837–31844
43. Nandi, A., Estess, P., and Siegelman, M. H. (2000) J. Biol. Chem. 275,
14939–14948
44. Chen, D., McKallip, R. J., Zeytun, A., Do, Y., Lombard, C., Robertson, J. L.,
Mak, T. W., Nagarkatti, P. S., and Nagarkatti, M. (2001) J. Immunol. 166,
5889–5897
45. Pure, E., and Cuff, C. A. (2001) Trends Mol. Med. 7, 213–221
46. Robinson, M. J., Tessier, P., Poulsom, R., and Hogg, N. (2002) J. Biol. Chem.
277, 3658–3665
47. de La Motte, C. A., Hascall, V. C., Calabro, A., Yen-Lieberman, B., and Strong,
S. A. (1999) J. Biol. Chem. 274, 30747–30755
48. Savani, R. C., Cao, G., Pooler, P. M., Zaman, A., Zhou, Z., and DeLisser, H. M.
(2001) J. Biol. Chem. 276, 36770–36778
49. Damle, N. K., Doyle, L. V., Bender, J. R., and Bradley, E. C. (1987) J. Immunol.
138, 1779–1785
50. Peace, D. J., and Cheever, M. A. (1989) J. Exp. Med. 169, 161–173
51. Baluna, R., Rizo, J., Gordon, B. E., Ghetie, V., and Vitetta, E. S. (1999) Proc.
Natl. Acad. Sci. U. S. A. 96, 3957–3962
52. Estess, P., Nandi, A., Mohamadzadeh, M., and Siegelman, M. H. (1999) J. Exp.
Med. 190, 9–19
53. Beekhuizen, H., and van de Gevel, J. S. (1998) Transplant Proc. 30, 4251–4256
54. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber,
J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., and White, D. E. (1994)
JAMA 271, 907–913
55. Malaguarnera, M., Ferlito, L., Gulizia, G., Di Fazio, I., and Pistone, G. (2001)
Eur. J. Clin. Pharmacol. 57, 267–273
56. Rosenberg, S. A. (2001) Nature 411, 380–384
The Role of CD44v7 in LAK-mediated Endothelial Cell Damage43830
